Knocking down FSTL1 reduces TGF-β2-induced trabecular meshwork fibrosis and ocular hypertension via inhibition of the Smad3 signaling pathway.
FSTL1 appears to be a key regulator of TGF-β2-induced trabecular meshwork fibrosis and ocular hypertension, but further research is needed to confirm its role in human conditions.
Where it sits
this study against the rest of the follistatin-344 corpusSummary and findings
This study investigated the role of Follistatin-like 1 (FSTL1) in TGF-β2-induced trabecular meshwork fibrosis and ocular hypertension. It utilized human trabecular meshwork cells and a murine model, reporting that silencing FSTL1 reduced ECM deposition and intraocular pressure. The findings suggest FSTL1's involvement in the regulation of these processes.
Abstract
<h4>Background</h4>Excessive accumulation of extracellular matrix (ECM) in the trabecular meshwork (TM) increases aqueous humor outflow resistance, leading to elevated intraocular pressure (IOP) and the development of primary open-angle glaucoma (POAG). Transforming growth factor-β2 (TGF-β2) is a well-established profibrotic mediator implicated in TM fibrosis. Despite its recognized role in promoting ECM deposition, the downstream regulatory mechanisms remain incompletely understood. Follistatin-like 1 (FSTL1), a secreted glycoprotein involved in various fibrotic diseases, has recently drawn attention, yet its role in TM fibrosis and IOP regulation in POAG remains unclear.<h4>Methods</h4>TGF-β2-induced human trabecular meshwork (HTM) cells and a murine model of TGF-β2-induced ocular hypertension were employed. Proteomic analysis, Western blotting, quantitative real-time PCR, and immunofluorescence were used to assess ECM expression and TGF-β2/Smad3 signaling. Loss-of-function approaches were applied to examine the role of FSTL1 in trabecular meshwork fibrosis and intraocular pressure regulation.<h4>Results</h4>FSTL1 was induced by TGF-β2 and associated with enhanced ECM accumulation and Smad3 activation in HTM cells. Silencing FSTL1 reduced TGF-β2 induced ECM deposition and p-Smad3 accumulation in vitro, and intraocular FSTL1 knockdown mitigated TM fibrosis and lowered TGF-β2-induced ocular hypertension in mice.<h4>Conclusion</h4>These findings identify FSTL1 as an important regulator of TGF-β2-induced TM fibrosis. FSTL1 contributes to ECM accumulation and IOP elevation with Smad3 signaling under profibrotic conditions. Targeting FSTL1 may represent a potential therapeutic strategy for limiting TM fibrosis and IOP elevation in POAG.
Background
The paper addresses the role of Follistatin-like 1 (FSTL1) in the context of trabecular meshwork fibrosis and ocular hypertension, conditions relevant to primary open-angle glaucoma (POAG). Prior research established TGF-β2 as a key mediator in ECM accumulation, but the specific mechanisms involving FSTL1 were not well understood. This study aims to clarify the involvement of FSTL1 in these processes.
Methods
The study employed TGF-β2-induced human trabecular meshwork (HTM) cells and a murine model to investigate the effects of FSTL1 knockdown. Various techniques including proteomic analysis, Western blotting, quantitative real-time PCR, and immunofluorescence were utilized to assess ECM expression and Smad3 signaling. The study focused on loss-of-function approaches to evaluate FSTL1's role in fibrosis and intraocular pressure regulation.
Results
FSTL1 was found to be induced by TGF-β2, correlating with increased ECM accumulation and Smad3 activation in HTM cells. The silencing of FSTL1 led to a reduction in TGF-β2 induced ECM deposition and p-Smad3 accumulation in vitro. Additionally, knockdown of FSTL1 in vivo resulted in decreased TM fibrosis and lowered TGF-β2-induced ocular hypertension in mice.
Interpretation
These findings suggest that FSTL1 plays a significant role in TGF-β2-induced trabecular meshwork fibrosis and may contribute to elevated intraocular pressure. While the results are statistically significant, the clinical relevance remains uncertain without human data. The use of a murine model and in vitro studies presents limitations that may affect the applicability of the findings to human conditions.
Key findings
- Silencing FSTL1 reduced TGF-β2 induced ECM deposition in vitro.
- Intraocular FSTL1 knockdown mitigated TM fibrosis in mice.
- FSTL1 was induced by TGF-β2 and associated with enhanced ECM accumulation and Smad3 activation.
Limitations
- small n in murine model
- in vitro findings may not translate to humans
- specific numeric findings related to IOP changes not detailed
- single-site study